The U.S. Food and Drug Administration has cleared Astellas Pharma (TYO:4503) and Pfizer's bladder cancer drug combination, PADCEV and Keytruda, according to a joint release on Friday.
The FDA cleared the combo for adults with severe bladder cancer to use before and after surgery.
This broadens a prior November 2025 approval that limited the drug's use to cisplatin-ineligible patients with muscle-invasive bladder cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments